Skip to main
COGT

COGT Stock Forecast & Price Target

COGT Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 36%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Cogent Biosciences is a clinical-stage biotechnology company focused on developing precision therapies for genetically defined diseases. With bezuclastinib, its lead program, in clinical trials for advanced systemic mastocytosis and gastrointestinal stromal tumors, as well as new potential therapies in the pipeline, Cogent is well-positioned to address significant unmet medical needs and potentially attract acquisition interest. Positive Phase 3 clinical results and potential FDA approval in multiple indications could drive future growth and increase shareholder value, while the company has a strong financial position with enough cash to support operations into 2028.

Bears say

Cogent Biosciences is facing key risks to its valuation, including potential disappointing results from its CGT9486 program, competition from other companies, and regulatory/commercial risks. With its recent 4Q25 earnings showing reiteration of timelines and a strong cash balance, Cogent Biosciences is focused on submitting its NDA for bezuclastinib in NonAdvSM by the end of this month and in 2L GIST in April, as well as advancing its pipeline including planned IND submissions for CGT1815 and CGT1145. However, with potential challenges ahead and a lack of near-term catalysts, we have a negative outlook on COGT stock.

COGT has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 36% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cogent Biosciences, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cogent Biosciences, Inc. (COGT) Forecast

Analysts have given COGT a Buy based on their latest research and market trends.

According to 11 analysts, COGT has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cogent Biosciences, Inc. (COGT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.